860 related articles for article (PubMed ID: 25754396)
1. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
[TBL] [Abstract][Full Text] [Related]
3. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
5. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Gallo S; Charbonnel B; Goldman A; Shi H; Huyck S; Darekar A; Lauring B; Terra SG
Diabetes Obes Metab; 2019 Apr; 21(4):1027-1036. PubMed ID: 30614616
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
9. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
[TBL] [Abstract][Full Text] [Related]
12. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
[No Abstract] [Full Text] [Related]
13. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
[No Abstract] [Full Text] [Related]
15. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Wu L; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
Curr Med Res Opin; 2020 Aug; 36(8):1277-1284. PubMed ID: 32324082
[No Abstract] [Full Text] [Related]
17. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Ji L; Liu Y; Miao H; Xie Y; Yang M; Wang W; Mu Y; Yan P; Pan S; Lauring B; Liu S; Huyck S; Qiu Y; Terra SG
Diabetes Obes Metab; 2019 Jun; 21(6):1474-1482. PubMed ID: 30830724
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Nardini C; Mannucci E
Diabetes Obes Metab; 2014 May; 16(5):457-66. PubMed ID: 24320621
[TBL] [Abstract][Full Text] [Related]
20. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
